ASX:LBT
One to watch
September 19, 2024
LBT Innovations
:
Cash flow positive in FY26

Venn Brown sat down with Brent Barnes, CEO and Managing Director of LBT Innovations, to discuss the company’s pivot into environment monitoring in the pharmaceutical manufacturing space, the launch of their new instrument, the AstraZeneca purchase, market size, the outlook of the pipeline, and the path to being cash flow positive.

AI-powered environment monitoring: LBT Innovations is the maker of the Automated Plate Assessment System (APAS), an AI-powered machine that automates the examination of culture plates used to monitor the clean room environments of pharmaceutical manufacturing facilities. APAS replaces a manual process involving two-person teams who physically examine up to 1,000 plates a day for signs of bacterial growth.

Market size: LBT estimates a total addressable market worth around $2.8 billion. More than 14,000 laboratories and manufacturing facilities globally are mandated to use culture plates for environmental monitoring. The market is highly fragmented, with the 20 largest pharmaceutical companies and contract drug manufacturers operating approximately 600 facilities.

Competition: Two competitors in the market are currently installed in an estimated 150 facilities. LBT’s APAS technology offers greater scalability than existing solutions, with the APAS Independence able to process 1,600 plates a day compared to <150 plates a day from the competitor machines. APAS is either the same price or cheaper, takes up less space and aligns better with customers’ existing workflow.

Traction: In 2023, AstraZeneca gave LBT $1.2 million to accelerate APAS development. AstraZeneca has just purchased five devices worth approximately $5 million over five years. Two other top 10 pharma companies are currently evaluating the technology.

Outlook: LBT aims to be cash flow positive by FY26. Having only launched APAS in March, the company is just starting to build a footprint in the industry. The response has been positive, with AstraZeneca evangelising the system at various conferences and through published papers. The company reports a solid two-year pipeline of potential sales, including another 5 – 10 devices for AstraZeneca.

‍

APAS processes 200 plates an hour with higher accuracy than manual reviews

Download full report
Other reports you may like
July 29, 2025
Earnings
Artrya
ASX:AYA
4Q25 results - SAPPHIRE progressing
Artray reported its 4Q25 cash flows yesterday. Operating cash flow was -$5.4 million with a step up in cash burn reducing operating cash flow. AYA is continuing to progress its SAPPHIRE study, with news on study partners expected in month or so. Costs in the quarter increased as AYA focused on submitting Silax Coronary Plaque for FDA approval (16th July 2025) and completing development of Silax Coronary Flow.
July 2, 2025
Industry & markets
Markets
Good, compared to what?
We review the relative performance of Australia’s leading indices and look at the long-term impact of underperformance. We also examine the fundamental limitation of the ASX Small Ordinaries index and why you should never passively invest in it.
June 16, 2025
Company update
Artrya
ASX:AYA
Salix Coronary Plaque submitted for FDA approval
Artrya announced today that it had submitted its application for approval by the FDA for its second product, Salix Coronary Plaque (SCP). The FDA aims to complete the approval process within 30 days, with the clock stopped if they request additional data. We also estimate that the 6-8 hospital groups Artrya are in discussions with about being part of its SAPPHIRE study could represent $4.5 billion in value.